Bioactive Materials,
Journal Year:
2022,
Volume and Issue:
22, P. 551 - 566
Published: Oct. 31, 2022
Cancer
therapy
is
undergoing
a
paradigm
shift
toward
immunotherapy
focusing
on
various
approaches
to
activate
the
host
immune
system.
As
research
identify
appropriate
cells
and
anti-tumor
immunity
continues
expand,
scientists
are
looking
at
microbial
sources
given
their
inherent
ability
elicit
an
response.
Bacterial
extracellular
vesicles
(BEVs)
actively
studied
control
systemic
humoral
cellular
responses
instead
of
using
whole
microorganisms
or
other
types
(EVs).
BEVs
also
provide
opportunity
as
versatile
drug
delivery
carriers.
Unlike
mammalian
EVs,
have
already
made
it
clinic
with
meningococcal
vaccine
(Bexsero®).
However,
there
still
many
unanswered
questions
in
use
BEVs,
especially
for
chronic
systemically
administered
immunotherapies.
In
this
review,
we
address
opportunities
challenges
cancer
outlook
towards
development
BEV
products
that
can
ultimately
translate
clinic.
Expert Opinion on Drug Delivery,
Journal Year:
2024,
Volume and Issue:
21(1), P. 45 - 70
Published: Jan. 2, 2024
Introduction
Exosomes,
a
type
of
extracellular
vesicles,
are
effective
tools
for
delivering
small-molecule
drugs
and
biological
therapeutics
into
cells
tissues.
Surface
modifications
with
targeting
ligands
ensure
precise
delivery
to
specific
cells,
minimizing
accumulation
in
healthy
organs
reducing
the
side
effects.
This
is
rapidly
growing
area
drug
research
this
review
aims
comprehensively
discuss
recent
advances
field.
ACS Applied Bio Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 12, 2025
As
we
progress
into
the
21st
century,
cancer
stands
as
one
of
most
dreaded
diseases.
With
approximately
in
every
four
individuals
facing
a
lifetime
risk
developing
cancer,
remains
serious
health
challenges
worldwide.
Its
multifaceted
nature
makes
it
an
arduous
and
tricky
problem
to
diagnose
treat.
Over
years,
researchers
have
explored
plenty
approaches
avenues
improve
management.
One
notable
strategy
includes
study
extracellular
vesicles
(EVs)
potential
biomarkers
therapeutics.
Among
these
EVs,
exosomes
emerged
particularly
promising
candidates
due
their
unique
characteristic
properties
functions.
They
are
small
membrane-bound
secreted
by
cells
carrying
cargo
biomolecules
such
proteins,
nucleic
acids,
lipids.
These
play
crucial
roles
intercellular
communication,
facilitating
transfer
biological
information
between
cell-to-cell
communication.
Exosomes
transport
cargoes
DNA,
RNA,
lipids
involved
cellular
reprogramming
promoting
cancer.
In
this
review,
explore
molecular
composition
exosomes,
significance
chemistry
development,
its
theranostic
application
well
research
complications
solutions.
Critical Reviews in Food Science and Nutrition,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 21
Published: March 19, 2025
Exosomes
are
nanoscale
particles
with
a
lipid
bilayer
membrane
that
were
first
identified
in
mammalian
cells.
Plant-derived
exosome-like
nanoparticles
(PELNs)
share
structural
and
molecular
similarities
exosomes,
including
lipids,
proteins,
microRNA
(miRNA),
plant-derived
metabolites.
Owing
to
their
unique
characteristics,
such
as
outstanding
stability,
low
immunogenicity,
high
biocompatibility,
sustainability,
PELNs
have
emerged
promising
natural
bioactive
agents
the
capacity
for
cross-kingdom
cellular
regulation.
Dietary
supplementation
PELNs,
particularly
from
fruits
vegetables,
has
demonstrated
health
benefits.
An
increasing
number
of
studies
indicated
beneficial
effects
on
colon
health.
This
review
summarizes
isolation
characterization
uptake,
distribution
after
oral
ingestion.
Furthermore,
this
emphasizes
interactions
between
gut
microbiota,
immune
system,
uptake
by
modulation
bacteria
metabolism,
responses
PELNs.
Additionally,
applications
components
drug
carriers
targeting
reviewed.
In
summary,
represent
versatile
approach
improve
health,
potential
both
therapeutic
preventive
healthcare
strategies.
Bioactive Materials,
Journal Year:
2022,
Volume and Issue:
22, P. 551 - 566
Published: Oct. 31, 2022
Cancer
therapy
is
undergoing
a
paradigm
shift
toward
immunotherapy
focusing
on
various
approaches
to
activate
the
host
immune
system.
As
research
identify
appropriate
cells
and
anti-tumor
immunity
continues
expand,
scientists
are
looking
at
microbial
sources
given
their
inherent
ability
elicit
an
response.
Bacterial
extracellular
vesicles
(BEVs)
actively
studied
control
systemic
humoral
cellular
responses
instead
of
using
whole
microorganisms
or
other
types
(EVs).
BEVs
also
provide
opportunity
as
versatile
drug
delivery
carriers.
Unlike
mammalian
EVs,
have
already
made
it
clinic
with
meningococcal
vaccine
(Bexsero®).
However,
there
still
many
unanswered
questions
in
use
BEVs,
especially
for
chronic
systemically
administered
immunotherapies.
In
this
review,
we
address
opportunities
challenges
cancer
outlook
towards
development
BEV
products
that
can
ultimately
translate
clinic.
